Skanska USA Building has signed a contract with a leading Bay Area
biotechnology company. The contract amounts to USD 70 M, about SEK 445
M, which will be included in order bookings for the second quarter 2011.
The scope of work will provide construction management. Skanska will
also move services for the company's campus in the region. Work will
commence this summer and continue over a three year period.
Skanska USA is one of the leading development and construction companies
in the country, consisting of four business units: Skanska USA Building,
which specializes in building construction; Skanska USA Civil,
specialized in civil infrastructure; Skanska Infrastructure Development,
which develops public-private partnerships; and Skanska Commercial
Development, which develops commercial development projects in select
U.S. markets. Headquartered in New York, Skanska USA has approximately
7,400 employees and its 2010 revenues were SEK 34.3 billion.
For further information, please contact:
Jay Weisberger, Communications Manager, Skanska USA, tel +1 206 494 5469
Edvard Lind, Group Press Officer, Skanska AB, Tel: +46 (0)10-448 88 08
Direct line for media: +46 10 448 88 99
This and previous releases can also be found at
Skanska AB may be required to disclose the information provided herein
pursuant to the Securities Markets Act.
Skanska is one of the world's leading project development and
construction groups with expertise in construction, development of
commercial and residential projects and public-private partnerships.
Based on its global green experience, Skanska aims to be the clients'
first choice for Green solutions. The Group currently has 52,000
employees in selected home markets in Europe, in the US and Latin
America. Headquartered in Stockholm, Sweden and listed on the Stockholm
Stock Exchange, Skanska's sales in 2010 totalled SEK 122 billion.